Randomized Trialhigh evidence
Asundexian versus Apixaban in Patients with Atrial Fibrillation.
The New England journal of medicine·January 2, 2025·PMID 39225267
Why it mattersFactor XIa inhibition is a promising strategy to reduce bleeding while preventing stroke, but this trial shows that asundexian 50 mg is not effective for stroke prevention compared to apixaban, despite fewer bleeds. This informs ongoing development of other factor XIa inhibitors and dosing strategies.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled